Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Ascending Dose, Open-Label Study Evaluating the Safety, Tolerability, And Pharmacokinetics of ALA-1000 in Opioid-Dependent Individuals

NCT04122755 is registered in ClinicalTrials.gov with Alar Pharmaceuticals Inc. as lead sponsor.

NCT NCT04122755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04122755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Ascending Dose, Open-Label Study Evaluating the Safety, Tolerability, And Pharmacokinetics of ALA-1000 in Opioid-Dependent Individuals
Lead sponsor
Alar Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 16, 2019
Completion date
May 3, 2021
Enrollment
59 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

opioid-use disorder